GlassScriptPhysician profile
Mariel Salais
NPI 1609539659
$2,871.03
in general payments reported to CMS, 2019-2025
19 companies · $409 in 2025
The $409 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $318 · 2022: $1,314 · 2023: $356 · 2024: $473 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,238.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,353.66 | 2021-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $280.98 | 2022-2024 | Jardiance, Emgality, Mounjaro |
| Janssen Pharmaceuticals, INC | $263.73 | 2022-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $258.66 | 2022-2023 | |
| Dexcom, INC. | $244.90 | 2024-2025 | Dexcom G6 Transmitter |
| Alexion Pharmaceuticals, INC. | $95.65 | 2022-2024 | Ultomiris |
| Sumitomo Pharma America, INC. | $57.37 | 2024-2025 | Gemtesa |
| Tonix Medicines, INC. | $43.60 | 2025 | Tonmya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.88 | 2025 | Jardiance |
| Merck Sharp & Dohme LLC | $33.59 | 2025 | Capvaxive, Gardasil 9 |
| Mannkind Corporation | $31.04 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $30.31 | 2025 | |
| Aimmune Therapeutics, INC. | $28.72 | 2025 | Vowst |
| Pfizer INC. | $24.74 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $21.56 | 2024 | Breztri |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $19.48 | 2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Si-Bone, INC. | $19.20 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.44 | 2022 | |
| Dynavax Technologies Corporation | $7.52 | 2024 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariel Salais listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.